Topics:
Radiation Oncology • Medical Oncology • Liver and Pancreas Tumors • Hepatocellular Carcinoma • Journal Club ft. NEJM publications
How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
Answer from: Medical Oncologist at Academic Institution
In IMbrave150, 63% of patients treated with atezolizumab/bevacizumab had extrahepatic spread of disease, and my recommendation for patients with extrahepatic involvement is for first line systemic therapy.
For patients with unresectable disease without extrahepatic spread, we take a multi-disciplin...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Unresectable HCC represents a broad group of HCC patients. For patients with liver limited disease without vascular invasion, I rely on tumor burden to determine whether to start with liver directed therapy versus systemic therapy. IN general, patients with multifocal bilobar or multilobar disease, ...